by Fred Dumais | Mar 17, 2022 | News Release
MONTREAL, QUEBEC , March 17, 2022 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2022...
by Fred Dumais | Mar 1, 2022 | News Release
Record revenues in 2021 of $13.6 million, up 81% over 2020 Annual Gross Margins for 2021, $4 Million, up 186% over 2020Q4-21 revenues of $3.4 million, up 53% over Q4-20Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®, three transformational...
by Fred Dumais | Feb 24, 2022 | News Release
Atectura and Enerzair also now reimbursed by the Non-Insured Health Benefits (“NIHB”) program of Indigenous Services Canada and Veteran Affairs Canada (“VAC”)Public reimbursement now includes Ontario, Quebec, Alberta, Manitoba, Nova Scotia, New Brunswick, NIHB and VAC...
by Fred Dumais | Feb 21, 2022 | News Release
MONTREAL, QUEBEC , February 21, 2022 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended...
by Fred Dumais | Jan 5, 2022 | News Release
Hesperco now available in approximately 300 stores under the Loblaws bannersClinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms MONTREAL, QUEBEC , January 5, 2022 – Valeo Pharma Inc. (CSE:VPH, OTCQB:VPHIF, FSE:VP2)...
by Fred Dumais | Dec 15, 2021 | News Release
Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population.More than 90% private insurance coverage across Canada MONTREAL, QUEBEC , December 15, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE:...
